Harold E Bays Selected Research

Hypercholesterolemia

12/2021	Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins.
12/2020	A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model.
9/2020	Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials.
1/2020	Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
1/2019	Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
8/2017	Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials.
7/2017	Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial.
3/2016	A lipidologist perspective of global lipid guidelines and recommendations, part 1: Lipid treatment targets and risk assessment.
10/2014	Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies.
7/2014	Colesevelam, Ezetimibe, and Patients With Type 2 Diabetes Mellitus: Characteristics and Clinical Outcomes From a Health Care Database.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Harold E Bays Research Topics

Disease

26	Dyslipidemias (Dyslipidemia) 01/2017 - 03/2002
23	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 03/2008
23	Hypercholesterolemia 12/2021 - 11/2002
17	Coronary Disease (Coronary Heart Disease) 01/2017 - 07/2004
15	Hypertriglyceridemia 01/2022 - 11/2002
12	Type 2 Diabetes Mellitus (MODY) 01/2022 - 07/2007
9	Obesity 01/2020 - 08/2004
9	Diabetes Mellitus 03/2017 - 09/2007
9	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2016 - 02/2005
7	Atherosclerosis 08/2017 - 03/2007
7	Flushing 09/2012 - 03/2003
6	Overweight 01/2020 - 09/2009
4	Inflammation (Inflammations) 01/2016 - 03/2008
3	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2022 - 01/2016
3	Body Weight (Weight, Body) 01/2020 - 09/2009
3	Weight Loss (Weight Reduction) 01/2020 - 11/2009
3	Respiratory Tract Infections (Respiratory Tract Infection) 12/2016 - 07/2007
3	Hypertension (High Blood Pressure) 03/2015 - 04/2008
3	Muscular Diseases (Myopathy) 11/2014 - 04/2006
3	Hypertrophy 07/2013 - 03/2008
3	Pancreatitis 09/2012 - 03/2008
3	Hyperlipidemias (Hyperlipidemia) 06/2012 - 11/2002
3	Metabolic Diseases (Metabolic Disease) 03/2011 - 01/2009
2	Myocardial Infarction 01/2021 - 12/2016
2	Gout 09/2020 - 01/2019
2	Hyperglycemia 09/2020 - 11/2007
2	Hypoglycemia (Reactive Hypoglycemia) 03/2017 - 01/2014
2	Infections 03/2017 - 04/2014
2	Insulin Resistance 07/2013 - 03/2007
2	Coronary Artery Disease (Coronary Atherosclerosis) 11/2012 - 03/2003
2	Nasopharyngitis 12/2008 - 07/2007
1	Prediabetic State (Prediabetes) 01/2022

Drug/Important Bio-Agent (IBA)

45	LipidsIBA 01/2022 - 03/2002
26	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 11/2002
25	Triglycerides (Triacylglycerol)IBA 08/2019 - 07/2003
23	LDL CholesterolIBA 12/2021 - 11/2002
19	oxidized low density lipoproteinIBA 12/2021 - 12/2002
16	HDL CholesterolIBA 08/2017 - 03/2003
14	CholesterolIBA 01/2016 - 11/2002
13	Ezetimibe (Zetia)FDA Link 12/2021 - 11/2002
12	Niacin (Nicotinic Acid)FDA LinkGeneric 01/2015 - 03/2002
12	Atorvastatin (Lipitor)FDA Link 10/2014 - 03/2003
10	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 07/2007
10	Simvastatin (Zocor)FDA LinkGeneric 07/2017 - 11/2002
10	Lipoproteins (Lipoprotein)IBA 05/2016 - 01/2003
8	eicosapentaenoic acid ethyl esterIBA 01/2022 - 02/2013
8	Rosuvastatin Calcium (Crestor)FDA Link 10/2014 - 12/2002
7	EstersIBA 01/2022 - 07/2007
7	8- hydroxy- 2,2,14,14- tetramethylpentadecanedioic acidIBA 01/2022 - 09/2013
7	MK-0524IBA 01/2015 - 03/2008
7	Colesevelam Hydrochloride (Welchol)FDA Link 07/2014 - 04/2006
6	Pharmaceutical PreparationsIBA 12/2020 - 07/2004
6	LDL Lipoproteins (beta Lipoproteins)IBA 08/2011 - 11/2002
5	Nonesterified Fatty Acids (NEFA)IBA 01/2022 - 03/2008
5	Eicosapentaenoic AcidIBA 01/2022 - 02/2013
5	ApolipoproteinsIBA 08/2017 - 04/2008
5	Pravastatin (Pravachol)FDA LinkGeneric 09/2007 - 12/2002
4	alirocumabIBA 08/2017 - 10/2014
4	C-Reactive ProteinIBA 08/2015 - 04/2006
4	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 09/2012 - 03/2007
4	Fenofibrate (CiL)FDA LinkGeneric 04/2011 - 04/2006
4	Lovastatin (Mevacor)FDA LinkGeneric 09/2007 - 03/2002
3	lipoprotein cholesterolIBA 11/2019 - 03/2016
3	Apolipoproteins B (ApoB)IBA 08/2017 - 04/2011
3	Biomarkers (Surrogate Marker)IBA 07/2017 - 11/2014
3	Bile Acids and Salts (Bile Acids)IBA 01/2016 - 10/2008
3	Metformin (Glucophage)FDA LinkGeneric 01/2012 - 10/2008
3	fenofibric acid FDA Link 09/2010 - 12/2008
2	CanagliflozinIBA 01/2017 - 04/2014
2	remnant-like particle cholesterolIBA 10/2016 - 04/2008
2	Apolipoprotein C-IIIIBA 05/2016 - 11/2011
2	MineralsIBA 01/2016 - 01/2016
2	FatsIBA 01/2016 - 01/2016
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2016 - 09/2013
2	CarbohydratesIBA 01/2016 - 01/2016
2	Hormones (Hormone)IBA 01/2016 - 01/2016
2	VitaminsIBA 01/2016 - 01/2016
2	Trace Elements (Biometals)IBA 01/2016 - 01/2016
2	Immunologic Factors (Immunomodulators)IBA 01/2016 - 01/2016
2	Proteins (Proteins, Gene)FDA Link 01/2016 - 01/2016
2	Creatine Kinase (Creatine Phosphokinase)IBA 11/2014 - 04/2006
2	Insulin (Novolin)FDA Link 07/2013 - 01/2012
2	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 02/2013 - 11/2011
2	Hemoglobin AIBA 01/2012 - 10/2008
2	lorcaserinIBA 03/2011 - 11/2009
2	prostaglandin D2 receptorIBA 12/2009 - 11/2008
2	HDL LipoproteinsIBA 02/2009 - 03/2003
2	ProstaglandinsIBA 01/2009 - 03/2008
2	Blood Glucose (Blood Sugar)IBA 01/2009 - 09/2007
2	TabletsIBA 11/2008 - 11/2004
2	Fish OilsIBA 03/2008 - 03/2007
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2022
1	AcidsIBA 01/2022
1	Docosahexaenoic AcidsIBA 01/2022

Therapy/Procedure

33	Therapeutics 12/2021 - 11/2002
5	Drug Therapy (Chemotherapy) 10/2016 - 09/2014
3	Glycemic Control 03/2017 - 07/2013
3	Bariatric Surgery 01/2016 - 07/2013
2	Blood Component Removal (Apheresis) 01/2016 - 11/2014
1	Duration of Therapy 01/2021